‹Àfi¡‚¾”O/…_…C…W…F…X…g/01-01

Size: px
Start display at page:

Download "‹Àfi¡‚¾”O/…_…C…W…F…X…g/01-01"

Transcription

1 Guidelines for the Diagnosis,Treatment and Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis (JCS 2004) h Circulation Journal Vol. 68, Suppl. IV,

2 ACT activated clotting time ADL activity of daily life APC activated protein C APTT activated partial thromboplastin time BMI body mass index CT computed tomography DIC disseminated intravascular coagulopathy DVT deep vein thrombosis ESC European Society of Cardiology FDA Food and Drug Administration HIT heparin-induced thrombocytopenia HOT home oxygen therapy ICOPER International Cooperative Pulmonary Embolism Registry INR international normalized ratio mt-pa mutant tissue-type plasminogen activator PAIMS Plasminogen Activator Italian Multicenter Study PCPS Percutaneous Cardiopulmonary Support PH pulmonary hypertension PIOPED Prospective Investigation of Pulmonary Embolism Diagnosis PT prothrombin time rt-pa recombinant tissue-type plasminogen activator SK streptokinase t-pa tissue-type plasminogen activator MRI magnetic resonance image MRV magnetic resonance venography UK urokinase UPET Urokinase Pulmonary Embolism Trial 1 a b Circulation Journal Vol. 68, Suppl. IV, 2004

3 1 C S C Leiden G20210A * , Virchow % 40 mmhg acute on chronic % % 30 % 2 ESC Goldhaber Massive Massive 90 mmhg 40 mmhg 15 Submassive Moderate to large Non-massive Small to moderate Circulation Journal Vol. 68, Suppl. IV,

4 % 50 % 6 % 30 % 2 8 % % % mmhg QOL % % % C S 43.9 % honeymoon period Circulation Journal Vol. 68, Suppl. IV, 2004

5 5 6 Riedel 30 mmhg % 30 % Homans D- 2 CT MRA a 3 b Circulation Journal Vol. 68, Suppl. IV,

6 No Yes X D- 1 CT MRA 2 PCPS Circulation Journal Vol. 68, Suppl. IV, 2004

7 2 PaO2 60 Torr SpO2 90 % PaO2 60 Torr SpO2 90 % 7 ml Kg NO PCPS 1 2 a a a a PCPS 3 5,000 1,400 17, Xa U ml APTT PT-INR PT-INR APTT APTT ml , , , , , ,840 6 APTT 5,000 1,400 6 APTT APTT ml Circulation Journal Vol. 68, Suppl. IV,

8 t-pa mmhg 110 mmhg 100,000 mm 3 50% EurHeart J 2000; 21: APTT urokinase rt-pa alteplase 2,400 2 mt-pa monteplase 27,500 kg 2 streptokinase urokinase ,400 kg 10 4,400 kg FDA 1978 FDA rt-pa alteplase 100 mg FDA FDA Food and Drug Administration mt-pa mutant tissue-type plasminogen activator rt-pa recombinant tissue-type plasminogen activator 1142 Circulation Journal Vol. 68, Suppl. IV, 2004

9 a 1 b 1 PT-INR pulse-spray 8Fr PTCA 6Fr mm 5Fr pigtail rotation catheter Angiojet Thrombectomy Hydrolyser Oasis Thrombectomy 1 b 2 b b b 5 CT PCPS PCPS Circulation Journal Vol. 68, Suppl. IV,

10 Gray % Meyer % 8 25 % Gulba 23 % % MRSA 1 2 a 6 a b Class a b a Circulation Journal Vol. 68, Suppl. IV, 2004

11 7 1 Hugh-Jones a PaCO2 35 Torr PaO2 70 Torr b AaDO2 AaDO2 30 Torr X a 18 mm b CTR 50% c a P b V1 R 5 mm R S 1 V5 S 7 mm R S 1 a b segmental defects 6 6 a pouch defectsb webs and bandsc intimal irregularitiesd abrupt narrowinge complete obstruction 5 1 a 25 mmhg b12 mmhg 3 4 a1 1 b2 2 c3 a1 1 b2 1 c3 Circulation Journal Vol. 68, Suppl. IV,

12 X 6 a pouch defects b webs and bands c intimal irregularities d abrupt narrowing e complete obstruction mmhg a b c d 1 2 CT 2 1 INR a 2 b 3 b 4 b 5 b Circulation Journal Vol. 68, Suppl. IV, 2004

13 4 5 back flow taping % PaO a CT Daily 300 dyne sec cm 5 Jamieson 1 30 mmhg 300 dyne sec cm NYHA Daily Jamieson San Diego 1 Jamieson % Circulation Journal Vol. 68, Suppl. IV,

14 Swan-Gantz Jamieson SVO2 90 % mmhg PCPS 7 3 PCPS ICU 2 3 PEEP PGE1 PGI2 Daily 11.7 % % Jamieson 8.7 % % Tscholl 10.1 % 7 69Thistlethwaite 6 % % NYHA % % % Circulation Journal Vol. 68, Suppl. IV, 2004

15 3 D- CT 3 D- 4 CT CT 1 D- a b 2 a CT MRV b 2 D mg 100 APTT a 3 PT-INR apt 3.0 PT-INR Class C S Circulation Journal Vol. 68, Suppl. IV,

16 Class 4800 kg kg 1 96 a 3 10 a a 4 b 5 1 a 2 a 3 a 4 a DVT % DVT % PE % PE % DVT deep vein thrombosis PE pulmonary thromboembolism Circulation Journal Vol. 68, Suppl. IV, 2004

17 ,000 APTT 3,500 4 APTT APTT ACT PT-INR PT-INR PT-INR C S 45 Circulation Journal Vol. 68, Suppl. IV,

18 1 2 3 a 4 a 5 a Circulation Journal Vol. 68, Suppl. IV,

急性型から慢性肺血栓塞栓症性肺高血圧症に移行した1例

急性型から慢性肺血栓塞栓症性肺高血圧症に移行した1例 Japanese Society of Pulmonary Embolism Research -JaSPER- ) MAA 1964 WagnerIio Iio 1965 137 79 58 5715,1SD 99mTc MAA 81mKr discrete defectmpd MDP MPD MDP PH MPD MDP PH PH MDP patchinessmottled

More information

METs WPW QT LQTS 9Brugada 0 METs 30 Circulation Journal Vol. 67, Suppl. IV,

METs WPW QT LQTS 9Brugada 0 METs 30 Circulation Journal Vol. 67, Suppl. IV, 2002002 Guidelines for Exercise Eligibility at Schools, Work-Sites, and Sports in Patients with Heart Diseases (JCS 2003) JR 2 3 2 3 2 2 3 2 2 3 Circulation Journal Vol. 67, Suppl. IV, 2003 309 2002002

More information

‹Àfi¡‚¾”O/Œ{ŁÒ/01-01

‹Àfi¡‚¾”O/Œ{ŁÒ/01-01 2002 2003 Guidelines for the Diagnosis,Treatment and Prevention of Pulmonary Thromboembolism and Deep Vein Thrombosis (JCS 2004) h 1 2 3 1 1 2 2-1 2-2 2-3 2-4 2-5 2-6 2 1 2 2-1 2-2 3 1 2 4 Circulation

More information

マニュアル第4版表紙PDF

マニュアル第4版表紙PDF 5 2004 4 1 5 2004 1968 1993 1994 1996 1998 2001 2004 3 I 1 1 2 2 3 12 4 24 5 48 6 59 7 65 8. 68 9 72 10 76 11 80 12 82 13 84 14 88 15 98 16. 106 17. (AIDS) 108 18 113 19 117 20 119 21 TPN 122 22 125 23.

More information

SpO2 FIO2 Hypoxic Pulmonary Vasoconstriction HPV 30 FIO2 FIO2 PaCO mL/kg I/E CPAP P

SpO2 FIO2 Hypoxic Pulmonary Vasoconstriction HPV 30 FIO2 FIO2 PaCO mL/kg I/E CPAP P 11 a. 2012 1 15 26 http://www1.koalanet.ne.jp/anesth_memorandum/sub19.html SpO2 FIO2 Hypoxic Pulmonary Vasoconstriction HPV 30 FIO2 FIO2 PaCO2 20 30 8 10mL/kg I/E CPAP PEEP 27 b. CO2 ( ) SpO2 COPD PETCO2

More information

31 Venous thromboembolism VTE Deep vein thrombosis DVT VTE DVT DVT VTE VTE VTE VTE VTE VTE VTE VTE 31.1 VTE (Elastic stocking ES) (Intermittent pneuma

31 Venous thromboembolism VTE Deep vein thrombosis DVT VTE DVT DVT VTE VTE VTE VTE VTE VTE VTE VTE 31.1 VTE (Elastic stocking ES) (Intermittent pneuma 31 Venous thromboembolism VTE Deep vein thrombosis DVT VTE DVT DVT VTE VTE VTE VTE VTE VTE VTE VTE 31.1 VTE (Elastic stocking ES) (Intermittent pneumatic compression ICP) (Low dose unfractionated heparin

More information

GL_高野班_D.indd

GL_高野班_D.indd Circulation Journal Vol. 72, Suppl. IV, 2008 1443 PCI CCU STEMI CABG ST ST1 EBM ST ST ST ST ST ST 1 EBMEvidence-Based Medicine 1444 Circulation Journal Vol. 72, Suppl. IV, 2008 ACS ST T ST CLBBB ST ACS

More information

終末期の呼吸困難症状への対応*松坂最終修正

終末期の呼吸困難症状への対応*松坂最終修正 Clinical Question 2017 5 27 1 PCOC 1. 12778 ( 55%, 45% NRS. 1 54, 35%. NRS. NRS,,,,,,,, Performance status, Ekstrom, M., et al.2016 J Pain Symptom Manage 51(5):816-23. . 1 85 ADL. 3,,,,. JCS200,, 40 /,

More information

A C A0 B C 1250 Circulation Journal Vol. 66, Suppl. IV, 2002

A C A0 B C 1250 Circulation Journal Vol. 66, Suppl. IV, 2002 20002001 Guidelines for Exercise Training in Patients with Heart Disease (JCS 2002) 1 1 2 3 4 5 6 7 8 Quality of Life 1QOL 2 QOL 3 QOL 4 QOL 1 2 2 3 1 2 Circulation Journal Vol. 66, Suppl. IV, 2002 1249

More information

DIC vegetation 1 nonbacterial thrombogenic e

DIC vegetation 1 nonbacterial thrombogenic e 2001 2002 Guidelines for the Prevention and Treatment of Infective Endocarditis (JCS 2003) h 1 1 2 3 4 5 6 7 8 9 2 1 2 3 1 2 3 4 1 2 5 1 2 1 G Streptococcus viridans Streptococcus bovis 2 G Streptococcus

More information

GL改訂_野原班DST.indd

GL改訂_野原班DST.indd Quality of Life QOL HRQL Circulation Journal Vol. 71, Suppl. IV, 2007 1 HRQL ASO ASO ASO ASO 2 Circulation Journal Vol. 71, Suppl. IV, 2007 evidence based medicine a a b A B C,, A Quality of LifeQOL HDL

More information

訪問入浴Q&A PDFファイ ル httpwww.care-mirai.commiraihomehelpe_buth.html.docx

訪問入浴Q&A  PDFファイ ル httpwww.care-mirai.commiraihomehelpe_buth.html.docx 4 450kg500kg 185cm 95kg 100kg 185 ( ) Vision , 40 8/138/15 1/11/3 1 13,000 11,700 9,500 3,500 13,000 11,700 9,500 3,500 http://www.care-mirai.com 1 37 38 1 1,000PPM soda premium 1,100ppm http://www.care-mirai.com/mirai/carbonated.html

More information

核 WG.indd

核 WG.indd 15 平成 25 年度ワーキンググループ報告 25 3 MDCT SPECT FDG-PET γ 8 16 25 MDCT SPECT 6 MDCT SPECT Dual source CT SPECT 5 (rt-pa) MDCT SPECT 2 MDCT SPECT 7 rt-pa 95% rt-pa 8.1% 17% 1) 65 rt-pa 7 rt-pa 2 MDCT (submassive

More information

PDFfl[ŁiŠp_Œ{Ł¶…g…fi…{Łt‡«.pdf

PDFfl[ŁiŠp_Œ{Ł¶…g…fi…{Łt‡«.pdf 診断 治療 技術講座 2018; 29 4 : 413-420 APTT 波形解析 APTT waveform Hideo WADA Key words: APTT, waveform, hemophilia, anticoagulant therapy 1978 1982 1982 1983 1985 NIH 1985 2000 / 2008 1 activated partial thromboplastin

More information

日本臨床麻酔学会 vol.35

日本臨床麻酔学会 vol.35 225 日本臨床麻酔学会第 33 回大会シンポジウム日臨麻会誌 Vol.35 No.2, 225 229, 2015 周術期肺血栓塞栓症 チーム医療による安全対策と医療紛争に対する心構え 周術期肺血栓塞栓症の第一発見者として果たすべき看護師の役割 * 木下佳子 [ 要旨 ] 静脈血栓塞栓症 (VTE) による死亡を防ぐために, 予防とともに VTE 発症時の早期発見と対処が重要である. 看護師が発見に至った症例から,

More information

DiMAGE Scan Multi PRO

DiMAGE Scan Multi PRO J 9229-2887-26 P-A111 9229-2887-24 X-A110 9229-2887-24

More information

無印良品 2012 自転車 カタログ

無印良品 2012 自転車 カタログ 26 897895321,000 140cm 76.0cm 16.0kg H LED 3 263 897896025,000 140cm 76.0cm 16.5kg H 3 LED 20 8978984 8978977 19,800 134cm 73.0cm 15.0kg LED 2620 2620 8486656550 5536207483 14512372,100 8279999840 26 77342561,417

More information

評価結果報告書の概要版(平成20年度)

評価結果報告書の概要版(平成20年度) 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76

More information

Microsoft Word - 平成24年度医学部卒業試験問題-2.docx

Microsoft Word - 平成24年度医学部卒業試験問題-2.docx 24 2012.10.25 13:00 15 00 5 2 10 20 60 80 110 10 1 6 7 /kg 1 12 20 30:2 AED 3 1 2 119 2 2 2 X X SpO 90% 60mmHg Primary Survey FAST CT 90% 100mmHg FAST 1 2L FAST(Focused assessment with sonography for trauma)

More information

障害者職域拡大カリキュラム研究会中間報告書構成案

障害者職域拡大カリキュラム研究会中間報告書構成案 3 4 5 5 7 7 9 () 9 ()23 34 1 36 47 49 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 ADL QOL 36 37 38 39 40 41 42 43 44 45 46 16 8 () 19 ( ) () 21 () 47 16

More information

1 FEV1.0 FEV1.0 30 80% NIH FEV1.0 50 80% FEV1.0 50% FEV1.0 cyanosis PaO2 PaCO2 PaO2 PaCO2 40mmHg FEV1.0 25% 2 1 1 2

1 FEV1.0 FEV1.0 30 80% NIH FEV1.0 50 80% FEV1.0 50% FEV1.0 cyanosis PaO2 PaCO2 PaO2 PaCO2 40mmHg FEV1.0 25% 2 1 1 2 15 1 12 1 2 2 2 2.1.............................. 3 2.2........................... 3 2.3 β........................ 6 2.4............................ 7 3 8 3.1....................... 8 3.2....................

More information

脳卒中医療体制検討特別委員会 Ⅰ. はじめに recombinant tissue plasminogen activator: rt-pa rt-pa J-MARS rt-pa D D Detection Dispatch Delivery Door Data Decision Drug. Act

脳卒中医療体制検討特別委員会 Ⅰ. はじめに recombinant tissue plasminogen activator: rt-pa rt-pa J-MARS rt-pa D D Detection Dispatch Delivery Door Data Decision Drug. Act 脳卒中医療体制検討特別委員会 Ⅰ. はじめに recombinant tissue plasminogen activator: rt-pa rt-pa J-MARS rt-pa D D Detection Dispatch Delivery Door Data Decision Drug. Act FAST 図 ₁ CPSS World Stroke Organization World Stroke

More information

ph

ph 14 12 9 3 4 1 7 1.1..................... 7 1.2 ph............................ 9 1.2.1...... 9 1.2.2.... 12 4.4..... 55 1.2.3 14 4.4.1......... 56 1.2.4............. 19 2 21 2.1.......... 21 2.2......................

More information

/ / A/ B 16/17 COPD 18mcg COPD COPD COPD 1

/ / A/ B 16/17 COPD 18mcg COPD COPD COPD 1 11 1 -------------------- 19 205.117/205.128 14/15 205.126A/205.126B 16/17 COPD 18mcg COPD 11.1 11.1.1 COPD 100 19 205.227 COPD 1 FEV1.0 %FEV1.0 70% 1 FEV1.0 / FVC 70% 2 1 200 3 40 COPD 1 10mg ACE 1 1

More information

PCI(percutaneous Coronary Intervention)

PCI(percutaneous Coronary Intervention) HP No.5 3 PCI HP No.5 3 PCI PCI Catheter Guide Wire Balloon Stent Guiding Catheter t-pa UK PCI PCI Filtering Collimating I.I. size X Framing I.I. Guiding Catheter Guide Wire size Balloon PCI PCI ACC American

More information

23 3 11 14 46 9.0 7 10m 40.1m 15,883 2,681 25 4 10 39 40 800 180 24 2425 22 21 24 5 3 21 24 10,899 20,472 13,723 33,007 667 400 79,167 8,620 11,694 10,089 25,131 690 215 56,439 13,614 20,897 15,200 32,213

More information

R E-DO

R E-DO 2005 ... 6... 7... 7... 7... 8... 8... 8... 9... 9...10...10...10...10...11...11...17...19... 20...20...20...20 R E-DO...21...21...21...22...22...22...23...23... 24 2 ICU...24...24...24...24...25...26...26...26...27...27...27

More information

untitled

untitled -1- -2- -4- -5- 20 30 12-6- 8 15 1-7- -8- -9- -10- 40 60-11- -12- 3 4 70 90-13- -14- 2 4 3 5-15- a 3-16- -17- -18- 128 kg 150 200g 100 200g 250 750g 2 1 94 89 89 81 72 390 97 97 83 83 75 97 97 100 86

More information

untitled

untitled 13 50 15 6.0 0.25 220 23 92 960 16 16 3.9 3.9 12.8 83.3 7 10 1150 90 1035 1981 1850 4700 4700 15 15 1150 1150 10 12 31 1.5 3.7%(224 ) 1.0 1.5 25.4%(1522 ) 0.7 30.6 1835 ) 0.7 1.0 40.3 (2421 ) 7.3

More information

21 8 20 70 1 1 2 1 1 20 12 22 16201835 2 21 1 21 15001910 3 21 2 23 15001750 4 21 3 23 15002030 5 21 4 27 15102010 6 21 6 15 15002110 7 21 7 27 15001910 2 3 3 21 3 21 4 2 4 1 2 1 2 312 4 3 1 2 3 4 2

More information

pp doi: /jjsps.54.6_ The 34th Autumn Symposium of The Japanese Society of Pediatric Surgeons

pp doi: /jjsps.54.6_ The 34th Autumn Symposium of The Japanese Society of Pediatric Surgeons 54 6 2018 10 pp. 1173-1193 doi: 10.11164/jjsps.54.6_1173 1173 34 The 34th Autumn Symposium of The Japanese Society of Pediatric Surgeons 30 2018 10 27 10-1 3-6-2 HP URL https://psjm2018.com/ 34 PSJM2018

More information

ケイセントラ_製品情報概要_H1-4_収載_新発売

ケイセントラ_製品情報概要_H1-4_収載_新発売 DIC 135-627 12 CONTENTS 34 32 33 1 2 K 34 3 4 5 12 12 18 24 3 31 31 31 33 KVKA K K VKA VKA K - PT-INR KC S 1996VKA VKA 3 KK CS 33 34 35 35 35 36 36 K 32 33 213 4VKA 12VKAFDA Kcentra 42 217 1 in vitro 1

More information

 

  10 44 1.2 5 4 5 3 6-1 - 1 2 3 4 5 1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8 9 10 TEL TEL 1 2 TEL FAX TEL FAX TEL FAX 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 1 2 3 4 5 6 ( ) ( ) 2

More information

2 はじめに 血栓症とは 140 2/3 4 DIC: disseminated intravascular coagulation 3 Virchow's triad : R. K. Virchow 表 1 各種静脈血栓症の発症要因 C S C Factor V Leiden*

2 はじめに 血栓症とは 140 2/3 4 DIC: disseminated intravascular coagulation 3 Virchow's triad : R. K. Virchow 表 1 各種静脈血栓症の発症要因 C S C Factor V Leiden* 1 総 説 血栓症治療薬の進歩 - 新しい経口抗凝固薬を中心に - 鈴木 宏治 キーワード :Xa DIC 要旨 NVAF DVT PE 3 Virchow's triad K Xa NVAF DVT PE 2 はじめに 血栓症とは 140 2/3 4 DIC: disseminated intravascular coagulation 3 Virchow's triad : R. K. Virchow

More information

6 12 10661 93100 227213202 222208197 85kg cm 20 64.521 106856142 2 1 4 3 9767 100 35 cm 7747 208198 90kg 23 5828 10661 93100 cm 227213202 10639 61 64.521 85kg 78kg 70kg 61 100 197204.5 cm 15 61

More information

<82D282A982C1746F95F18D908F57967B95B E696E6464>

<82D282A982C1746F95F18D908F57967B95B E696E6464> 1 2 (90cm 70cm 2015) 3 (68cm 28cm 30cm 12kg 2015) (77.5 109.5cm 2015) 4 (22cm 50cm 50cm 4.6kg 2015) (45cm 62.5cm 2015) (47.4cm 62.5cm 2014) 5 (28.5cm 23.5cm) (45cm 62cm 2015) (97cm 107cm 2015) 6 7 8 9

More information

180 140 22

180 140 22 21 180 140 22 23 25 50 1 3 350 140 500cm 600 140 24 25 26 27 28 29 30 31 1/12 8.3 1/15 6.7 10 1/8 12.5 1/20 140 90 75 150 60 150 10 30 15 35 2,000 30 32 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 9 % 100 50 33.3

More information

untitled

untitled 5 K 5 3 HP http://www.mhlw.go.jp/bunya/shakaihosho/iryouseido01/taikou03.html 2004 1 2 1 http://www.dm-net.co.jp/calendar/2007/06/005835.php 6 85cm 100cm 2 90cm 2 TG 150mg/dl HDLHDL-C 40mg/dl 130mmHg 85mmHg

More information

QOL 02 QOL QOL UI AI EAThoracotomy TTThoracoscopy TS QOL EA type-c y score UI 3 AI 8 School score QOL score 12

QOL 02 QOL QOL UI AI EAThoracotomy TTThoracoscopy TS QOL EA type-c y score UI 3 AI 8 School score QOL score 12 54 1 2018 2 4-1 OK-432 1 15 14 15 US CT MRI 17 cm 0.16 g/kg/day OK-432 3 1 ke 2 2 ke 3 1 1,150 ml 13 US OK-432 4-2 TJ-28 TJ-28 2003 3 2017 6 250 TJ-28 44 16 28 TJ-28 7 2 46 8.5 2 2 9 34 79.1 10 23.3 34

More information

21 5 I C T J-Doit High risk Risk 20 7 21 34,324 30,858 38,735 26,800 27,490 20,472 18,533 20,096 14,913 14,931 488 470 491 435 446 10 t-pa intervention t-pa interventionclipping simulator subspecialty

More information

10 117 5 1 121841 4 15 12 7 27 12 6 31856 8 21 1983-2 - 321899 12 21656 2 45 9 2 131816 4 91812 11 20 1887 461971 11 3 2 161703 11 13 98 3 16201700-3 - 2 35 6 7 8 9 12 13 12 481973 12 2 571982 161703 11

More information

0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2

0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2 24 11 10 24 12 10 30 1 0.45m1.00m 1.00m 1.00m 0.33m 0.33m 0.33m 0.45m 1.00m 2 23% 29% 71% 67% 6% 4% n=1525 n=1137 6% +6% -4% -2% 21% 30% 5% 35% 6% 6% 11% 40% 37% 36 172 166 371 213 226 177 54 382 704 216

More information

Journal Club

Journal Club Hikarigaoka Journal Club DVT に IVC フィルターは必要? 練馬光が丘病院総合内科 PGY-4 五味渕智香監修 : 筒泉貴彦 1. 症例 2. 論文の背景 3. 介入方法 4. UFH と LMWH 5. 結果 6. 批判的吟味 7. 本患者への適用 8. ガイドライン Agenda 症例 84 歳 女性 気管支喘息の既往あり ADL full 入院数日前から悪寒 咽頭痛

More information

[] 1

[] 1 0 [] 1 [] 2 [] 2010 22 0% 20% 40% 60% 80% 100% 15.4 65.2 10.8 8.6 12,000 2010 22 2020 32 2030 42 2040 52 2015 27 14.3 63.3 12.3 10.1 10,000 2020 32 13.2 63.0 11.9 11.9 8,000 2025 37 12.3 62.9 10.6 14.2

More information

緑化計画作成の手引き 26年4月版

緑化計画作成の手引き  26年4月版 http://www.city.shibuya.tokyo.jp/env/en_eventact/midori_ryokka.html 10 11 12 13 14 15 16 17 18 19 P10 P10 1 P12 2635 Fax (1) 47 03-5388-3554 http://www2.kankyo.metro.tokyo.jp/sizen/sinseisyo/e2/tebiki.htm

More information

GL_小川(聡)班_D.indd

GL_小川(聡)班_D.indd J-RHYTHM Pill-in-the-pocket Up-stream Circulation Journal Vol. 72, Suppl. IV, 2008 1639 Sicilian GambitSicilian Gambit CAST Sicilian Gambit Sicilian Gambit Sicilian Gambit Sicilian Gambit CD-ROM ACC/AHA/ESC

More information

医療レーザー脱毛の威力と限界

医療レーザー脱毛の威力と限界 .... mm. CT WH W H W H W H... kcalkcal. 1. cal kcal 1 6 2 3. 4. 5. 1 6 6. B6 B12 B. BMI BMI30 C. D. kg mm . CT WH W H W H W H... kcalkcal . 1. cal kcal 1 6 2 3. 4. 5. 1 6 6. B6 B12 B. BMI BMI30 C. D.

More information

() 90

() 90 1 () 90 15 I 20 20 1 8.5 6.2 AED 17.5 10 9.810 4.5 119 1 119 VF VF 710 CPR 119 119 1 1 3 119 3 180 240 480 24 8 24 16 3 3 1 4 8 119 AED AED 1 8 1 3 1 4 5 3 2 2 AED 3 119 AED 119 AED 119 10 100 30 2 30:2

More information

untitled

untitled 8ppm 2 2.7 a/a Arterial-alveolar oxygen ratio a/a PaO 2 P A O 2 A-aDO 2 Alveolar arterial oxygen tension difference gradient A-aDO 2 P A O 2 PaO 2 ACT Activated clotting time aptt Activated partial thromboplastin

More information

HEM-7041 1 2 Q A A Q A A A A Q A A A Q A Q A Q A (mmhg) 180 160 140 130 120 (mmhg) 80 85 90 100 110 *International Society of Hypertension HEM-7041 This warranty is valid

More information

untitled

untitled Microsoft Excel 1. 2. 3. 4. VBA) A IV 256 BMI (Body Mass Index) AVERAGE,COUNTIF BMI ( kg ) = 22 ( m) 2 BMI (Body Mass Index) BMI = ( kg ( m ) ) 2 BMI BMI 20 BMI 20 24 BMI 24 26.5 BMI 26.5 E1 kg Del Back

More information

Ł\”ƒ1-4

Ł\”ƒ1-4 1 2 (1) 4 (2) 4 (3) 5 (4) 7 (5) 7 (1) 8 (2) 11 (3) 12 (4) 13 (5) 14 (6) 19 (1) 20 (2) 22 (3) 24 (4) 10 27 (5) 28 (1) 34 (2) 39 (3) 42 (4) 45 (1) 52 (2) 66 (3) 67 (4) 69 (1) 71 (2) 71 (3) 72 (4) 72 (5)

More information

1 2 3 4 5 68g 9g 2g 0.2mg 0.8mg 316kcal 316cal 326kcal 326cal 6 010 3035 15 5355 30 120 20 7 8 9 10 11 () () () 12 1 3 1 5 1 80kcal 20 30 20 30 1 9 7.5 13 7.58.5 910.5 1213.5 11.512.5 14 15 79 23 1520

More information

GABA GABA

GABA GABA ( ) ITB QA ITB ITB intrathecal baclofen therapy GABA GABA 27mm 70mm g 18mL 9cm 5cm 2 1 24 2.5kg 2 13 1 416 57 25 6 20 6 19 1 2 MRl 1 2 QA 18 4 1 1 2 1 2 1 http //www.shakyo.or.jp / pamphlet.html QOL

More information

44 Fig. 1 Fluoroscopy showing that A) both leaflets functioned well after the first atrioventricular valve replacement; B) one leaflet was fixed at th

44 Fig. 1 Fluoroscopy showing that A) both leaflets functioned well after the first atrioventricular valve replacement; B) one leaflet was fixed at th 症例報告 PEDIATRIC CARDIOLOGY and CARDIAC SURGERY VOL. 27 NO. 1 (43 48) 房室弁置換術後の血栓弁に対し recombinant tissue plasminogen activator による血栓溶解療法を施行した単心室幼児例 1 1 1 1 1 1 2 2 3 3 3 1 2 3 Key words: prosthetic valve

More information

消費データ付きアンケート作成マニュアル

消費データ付きアンケート作成マニュアル ... 3... 4... 4... 5... 6... 6... 7... 8... 9... 11... 15... 16... 18... 19... 22... 26... 26... 27... 27... 27... 28... 29... 30... 31... 35... 36... 37... 37... 38... 39... 40...41... 42... 43... 44...

More information

AHA ACC Class Class Class Class critical 1 High risk 4 METS Canadian Class 2 Canadian Class Q 3 ST-T S3 11

AHA ACC Class Class Class Class critical 1 High risk 4 METS Canadian Class 2 Canadian Class Q 3 ST-T S3 11 2001 2002 Guidelines for perioperative cardiovascular evaluation and management for noncardiac surgery (JCS 2003) 1 2 3 1 2 3 4 5 6 7 8 9 Circulation Journal Vol. 67, Suppl. IV, 2003 1239 2001 2002 13

More information

消費データ付きアンケート作成マニュアル

消費データ付きアンケート作成マニュアル ... 3... 4... 4... 5... 6... 6... 7... 8... 9... 14... 16... 17... 20... 24... 24... 25... 25... 25... 26... 27... 28... 29... 33... 34... 35... 35... 36... 37... 38... 39... 40... 41... 42... 43... 44...

More information

35 40mmHg PaCO2 40mmHg 35mmHg CO2 PETCO2 CO2 CO2 10mmHg CPR CO2 10mmHg ROSC() CO mmHg ROSC return of spontaneous circulation ROSC 17mmHg ROSC 20

35 40mmHg PaCO2 40mmHg 35mmHg CO2 PETCO2 CO2 CO2 10mmHg CPR CO2 10mmHg ROSC() CO mmHg ROSC return of spontaneous circulation ROSC 17mmHg ROSC 20 2010 ACLS Circulation Nov.2,2010 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care p640-p767 2010BLS 2010ACLS BLS Circulation, Nov2.2010 2010

More information

07.報文_及川ら-二校目.indd

07.報文_及川ら-二校目.indd 8 01 01 4 4 1 5 16 18 6 006 H 18 4 011 H 6 4 1 5 1 5 007 H 19 5 009 1 5 006 007 009 011 9 10 4 000 H 1 4 5 004 H 16 4 004 009 H 1 5 4 4 5 1 4 006 011 1 1 4m 5m 10m 007 1 7 009 009 1 5 10 1 000kg 10a 006

More information

JPドメイン名レジストリレポート 2013

JPドメイン名レジストリレポート 2013 2013.1-12 Registry Report Registry Report Index 03 06 19 21 02 22 23 24 25 26 27 28 29 31 34 35 36 Registry Report 01 02 Registry Report Registry Report 03 04 Registry Report Registry Report 05 06 Registry

More information

ml ml ml mg ml ml mm mm mm mm mm mm mm mm mm mm mm ml mmhg mmhg ml Acetylcholine ml mg mm mm mm mm mm mm ope ++ Uribe Davis S H S S : : : : : : : : : G

More information

橡マニュアル1999.PDF

橡マニュアル1999.PDF 11 11 7 28 7 30 9 30 16 30 2-302 1. (hardware) Microsoft Excel Microsoft Word Windows95/98 OS Windows95/98 MS-DOS 2. 3. 1 1 2 4. Enter CTRL ALT ALT SHIFT ESC BS DEL INS TAB CAPS 5. 1 ID ID 2 ID 3-1 - 6.Windows95/98

More information

2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ ,

2010 年 6 月 25 表 身体所見 134 cm 31 kg /60 mmhg 83/ , 24 シンポジウム Ⅲ 要旨 NPPV NPPV 緒 IPF 4 5 1 IPF 2004 2 QOL 179 10 現 10 18 2008 10 言 状 3.4 8.3 76.2 41 37.2 13.6 3 1 症 例 呈 示症例 患者 61 主訴 既往歴 30 45 家族歴 喫煙歴 飲酒歴 職歴 現病歴 13 NSIP 15 1 HOT 15 7 2010 年 6 月 25 表 1 1998

More information

untitled

untitled 1 2 2 2 3 3 4 4 5 9 6 9 7 10 8 13 1 34 2 46 1 46 2 51 3 54 4 58 5 64 72 74 76 78 80 81 82 86 90 94 98 99 99 100 104 106 108 112 113 114 115 116 117 118 119 119 120 121 122 123 123 124 124 125 125 126 126

More information

北辰同窓会36号-02.21修正

北辰同窓会36号-02.21修正 36 FEB, 2011 20112 36 1 GDPOECD 1.5 0.1910 1 2 4 29 Web 40 3,500 22 9 1 22 4 3,279 6 6 6 6 22 7 28 208 1971 9 1976 3 1976 4 1977 11 1983 7 1989 5 Russell Ross 1990 5 1994 7 2002 4 2004 8 1122 9 125 8 313

More information

橡アロマセラピー症状別処方例.PDF

橡アロマセラピー症状別処方例.PDF 1 1 92 E 100ml 1 2 2 1 93 0.5m 10ml 100ml 1 2 3 2 52 0. l 2 4 3 27 3 1 1 3 3 4 5 3 2g 2 3 1 1 1 10ml 3 4 6 3 29 2 2 2 10ml 3 3 4 7 3 30 2 1 2 10ml 3 3 4 8 3 31 1 1 1 1 3 60 10 10 3 2 4 10ml A 2 3 61 20

More information

Journal Club 2017/05/30 Tomohiro Matsumoto PGY-2

Journal Club 2017/05/30 Tomohiro Matsumoto PGY-2 Journal Club 2017/05/30 Tomohiro Matsumoto PGY-2 本 の論 March 21, 2017 2 Introduc)on 3 : (CIN) 3 25% 44µmol/L(0.5mg/dL) CIN 4 European Society of Urogenital Radiology. ESUR guidelines on contrast media,

More information

% % % ml % 500 ml von Willebrand Eisenmenger mmhg 3

% % % ml % 500 ml von Willebrand Eisenmenger mmhg 3 2003 2004 Guidelines for Indication and Management of Pregnancy and Delivery in Women with Heart Disease (JCS 2005) 1 2 1 2 3 4 5 6 3 1 1 2 3 4 5 6 7 8 9 2 1 2 3 4 Circulation Journal Vol. 69, Suppl. IV,

More information

救急車同乗実習レポート 総括

救急車同乗実習レポート 総括 14 9 1 9 10 10 19:00 23:00 52 1 6.5 40 CT X CT Ope 15 /min BP 100/70mmHg HR 96 /min O U m 60 25/min BP 140/80mmHg HR 55 O Spo 98 BP 172/68mmHg O 30 15 /min BP 100/60mmHg HR 80 /min BS O O CO 30 40 JCS

More information

8 8 0

8 8 0 ,07,,08, 8 8 0 7 8 7 8 0 0 km 7 80. 78. 00 0 8 70 8 0 8 0 8 7 8 0 0 7 0 0 7 8 0 00 0 0 7 8 7 0 0 8 0 8 7 7 7 0 j 8 80 j 7 8 8 0 0 0 8 8 8 7 0 7 7 0 8 7 7 8 7 7 80 77 7 0 0 0 7 7 0 0 0 7 0 7 8 0 8 8 7

More information

14 00 14 50 3DO3-1 DO3-5 DO3-1 DO3-2 DO3-3 DO3-4 DO3-5 1 1 2 3 3 3 3 3 3 3 1.2. 3. 15 1 2 3 1. 2. 3. 1, 2 2, 3 1, 2 1. 2. JSEPTIC 3. ICU 1 2 1.2. 医 一

14 00 14 50 3DO3-1 DO3-5 DO3-1 DO3-2 DO3-3 DO3-4 DO3-5 1 1 2 3 3 3 3 3 3 3 1.2. 3. 15 1 2 3 1. 2. 3. 1, 2 2, 3 1, 2 1. 2. JSEPTIC 3. ICU 1 2 1.2. 医 一 第 1 日 目 第 1 日 目 (2 月 9 日 ) 一 演 題 医 師 部 門 演 第 6 会 場 ホテル 日 航 東 京 3F レインボーテラス 9 00 9 50 1 DO1-1 DO1-5 DO1-1 DO1-2 DO1-3 DO1-4 DO1-5 Presepsin LPS PGC-1 1 2 3 2 3 1 1. 2.3. Critical illness polyneuropathy

More information

64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () m/s : : a) b) kg/m kg/m k

64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () m/s : : a) b) kg/m kg/m k 63 3 Section 3.1 g 3.1 3.1: : 64 3 g=9.85 m/s 2 g=9.791 m/s 2 36, km ( ) 1 () 2 () 3 9.8 m/s 2 3.2 3.2: : a) b) 5 15 4 1 1. 1 3 14. 1 3 kg/m 3 2 3.3 1 3 5.8 1 3 kg/m 3 3 2.65 1 3 kg/m 3 4 6 m 3.1. 65 5

More information

日医総研ワーキングペーパー

日医総研ワーキングペーパー DRG 64 14 DRG IR-DRGJ-DRG R 2 NHS-Clinical Indicators PCICABG 36 250,418 9,286 11 10 0.4 HCFA-DRGAP-DRGAPR-DRGJ-DRG( ) IR-DRG(International Refined-DRG) J-DRG IR-DRG938 267 J-DRG( ) R J-DRG(0.3070) IR-DRG0.3905

More information

The Lancet NPPV July18, 2009 Non-invasive ventilation in acute respiratory failure ( Review)The Lancet, vol. 374, July 18, 2009 H22.9 The Lancet 2009

The Lancet NPPV July18, 2009 Non-invasive ventilation in acute respiratory failure ( Review)The Lancet, vol. 374, July 18, 2009 H22.9 The Lancet 2009 The Lancet NPPV July18, 2009 Non-invasive ventilation in acute respiratory failure ( Review)The Lancet, vol. 374, July 18, 2009 H22.9 The Lancet 2009 7 18 NPPV NIV: non-invasive ventilation review NPPV(Non-invasive

More information

M1 TSH T 3 T 4 2 T 1 2 Plummer 3 TSH TSH K 5 7 TSH TSH Plummer TSH TSH TSH TSH T 4 T 3 TSH T 4 T 3 TSH TSH or Plummer Plummer or a) 1. 2. 3. b) 1. T 4 T 3 2. TSH 0.1 U/ml 3. TSH TRAb TSAb 4. 1) a) 1

More information

−Û”RflÇ-…_…C…W…F…X…g-01

−Û”RflÇ-…_…C…W…F…X…g-01 2004-2005 Guidelines for Treatment of Acute Heart Failure (JCS 2006) h Y 2006 11 1 2 2-1 2-2 3 3-1 3-2 1 2 2-1 2-212 2-3 2-4 X 2-5 3ICUCCU 3-1 3-2 3-3 3-4 1 1-1 1-2 1-3 1-4 1-5 2 3 4 4-1 4-2 4-3 1 2004-2005

More information

12-7 12-7 12-7 12-7 12-8 12-10 12-10 12-10 12-11 12-12 12-12 12-14 12-15 12-17 12-18 10 12-19 12-20 12-20 12-21 12-22 12-22 12-23 12-25 12-26 12-26 12-29 12-30 12-30 12-31 12-33 12-34 12-3 12-35 12-36

More information

MNT MNT CVD MNT 1) 2) 3) 4) MNT 1) 1 2 2) MNT MNT MNT MNT 1 1 2 1 % HbA1C 2

MNT MNT CVD MNT 1) 2) 3) 4) MNT 1) 1 2 2) MNT MNT MNT MNT 1 1 2 1 % HbA1C 2 2008 American Diabetes Association, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2008 Jan; 31 Suppl 1: S61-S78.

More information

untitled

untitled 30803040 1015 1 2 3 4 5 6 60 7 8 [ ] [] [ ] / 9 10 [] [] [] / () 11 12 61 13 Borg 14 15 16 mm mm 17 () BMI 200mg/dl 18 Anderson 200mmHg 120mmHg 40mmHg 20mmHg 62 AED 19 20 () 21 22 23 24 63 25 26 27 28

More information

PTCA CABG 2PTCA & CABG 3 4 PTCA CABG 1 2 3PTCA & CABG 4 5 PTCA CABG follow-up Japanese Circulation Journal Vol. 64, Suppl. IV, 2000

PTCA CABG 2PTCA & CABG 3 4 PTCA CABG 1 2 3PTCA & CABG 4 5 PTCA CABG follow-up Japanese Circulation Journal Vol. 64, Suppl. IV, 2000 19981999 JR PTCACABG 1 2 PTCA 3 PTCA 4 OP-CABG MID-CAB PTCACABG 1 PTCA PTCA CABG 2 1 PTCA PTCA PTCA PTCA PTCA 2CABG CABG CABG CABG 3PTCA CABG Japanese Circulation Journal Vol. 64, Suppl. IV, 2000 1009

More information

1 1 2 2 3 3 4 5 5 6 6 7 7 8 8 9 9 10 10. 11 1 12 1 13 2 13 3 8 13 4 14 5 14 6 14 7 15 8 15 1 17 2 22 3 24 4 24 1 33 2 42 1 49 2 50 3 50 4 56 1 60 2 88 3 93 1 95 2 96 1 98 2 100 1 100 2 104 3 105 4 105

More information

A A OT 2 A OT A OT A A OT 4 OT A A OT A OT A OT A 3 OT 1 2 OT 2 2 1 2014105 26.5.12 26.5.27 26.6.4 26.9/116 OTPT 10/101 26.9.292 26.6/26 26.5/2727.5/31 2/ 2/ H26.10.177 26.10.21 22 27.2 27.3 27.4.1 27.4.21

More information

日本呼吸器学会雑誌第45巻第2号

日本呼吸器学会雑誌第45巻第2号 ADL: Feeding Transfer Dressing Bathing IADL: Shopping Transportation Table1 Spector-KatzIndex * ADL-IADLisevaluatedbythesum ofeachscore(0:totaly dependent,6:totalyindependent) Table2 Generalcharacteristicsofthepatients

More information

上肢深部静脈血栓症による致死性肺塞栓症の 1 例 表 1 入院時検査所見. < 血算 > Ca 8.5 mg/dl CK 402 IU/l WBC 10100/μl IP 10.8 mg/dl CK-MB 53 IU/l RBC /μl Fe 10 μg/dl T-CHO 84

上肢深部静脈血栓症による致死性肺塞栓症の 1 例 表 1 入院時検査所見. < 血算 > Ca 8.5 mg/dl CK 402 IU/l WBC 10100/μl IP 10.8 mg/dl CK-MB 53 IU/l RBC /μl Fe 10 μg/dl T-CHO 84 症例報告 PCPS を挿入し社会復帰し得た上肢深部静脈血栓症による致死性肺塞栓症の 1 例 A Patient of Fatal Pulmonary Embolism Due to Upper-Extremity Deep Vein Thrombosis Who Was Able to Return Society, Using Percutaneous Cardiopulmonary Support

More information

Medical Journal of Aizawa Hospital

Medical Journal of Aizawa Hospital Medical Journal of Aizawa Hospital Medical Journal of Aizawa Hospital Medical Journal of Aizawa Hospital Medical Journal of Aizawa Hospital Vol. 6 Suppl. 1 (2008) Key words Medical Journal of Aizawa

More information

JHN Journal Club 手稲渓仁会病院

JHN Journal Club 手稲渓仁会病院 JHOSPITALIST network GUIDE-IT trial; The Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure multicentre randomised clinical trial 20171010 1 70 (EF 30%), (PCI), (HbA1c

More information

272 日本呼吸ケア リハビリテーション学会誌第 22 巻第 3 号 表 1 Variables Value Age, yr Sex Male 81 Female 12 Height, cm Body weight, kg 6

272 日本呼吸ケア リハビリテーション学会誌第 22 巻第 3 号 表 1 Variables Value Age, yr Sex Male 81 Female 12 Height, cm Body weight, kg 6 2012 年 12 月 271 第 22 回日本呼吸ケア リハビリテーション学会学術集会 ( 福井 ) 奨励賞 受賞報告 特発性肺線維症における呼吸困難感, 運動 耐容能,QOL を含む多面的評価の重要性 要旨 IPF QOL IPF modified MRC modified MRC 6 SpO 2 modified MRC IPF IPF 6 QOL IPF QOL は じ め に 24 11

More information

...J......1803.QX

...J......1803.QX 5 7 9 11 13 15 17 19 21 23 45-1111 48-2314 1 I II 100,000 80,000 60,000 40,000 20,000 0 272,437 80,348 82,207 81,393 82,293 83,696 84,028 82,232 248,983 80,411 4,615 4,757 248,434 248,688 76,708 6,299

More information

.k....-._.C.W.F.X.g01-01

.k....-._.C.W.F.X.g01-01 20042005 Guidelines for the Clinical Application of Bypass Grafts and the Surgical Techniques (JCS 2006) 2006 11 1 2 2.1 2.1.1 CCAB 2.1.2 2.1.3 2.1.4 2.1.5 2.1.6 2.1.7 2.2 2.2.1 MIDCAB 2.2.2 2.3 CCAB OPCAB

More information

- 1 - 15 2030 4 21 21-2 - 2 1 21 21 4 22 31 10 5 26 ( JA ) - 3 - 4 21 7 9 9 34 1,386 1,003 94 58 1,155 60 25 33 1 3 2-4 - 12 17 60 7 7 12 H1217 4 7 30 34 19-5 - - 6 - (BMI*18.5) 20 15.2%30 8.% 20 86.4%30

More information

(1)...3 (2)...5 (3)...6 (4) (1)...9 (2)...10 (3)...13 (4) 14 (5) (1)...16 (2) (1)...21 (2)...22 (3)

(1)...3 (2)...5 (3)...6 (4) (1)...9 (2)...10 (3)...13 (4) 14 (5) (1)...16 (2) (1)...21 (2)...22 (3) ...1...3...3 (1)...3 (2)...5 (3)...6 (4)...7...9 (1)...9 (2)...10 (3)...13 (4) 14 (5)...15...16 (1)...16 (2)...19...21 (1)...21 (2)...22 (3)...24...26...26 (1)...26 (2)...28 (3)...30 (4)...31 (5)...35

More information